- Conditions
- Healthy
- Interventions
- Alprazolam Extended-Release Tablets 1 mg, Xanax XR Tablets 1 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 2,243
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 117
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 18
- States / cities
- Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
- Conditions
- Healthy Volunteer
- Interventions
- GSK1349572, Placebo, Omeprazole
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gait
- Interventions
- Gait Training, Functional electrical stimulation (FES), Peripheral electrical stimulation paired with cortical magnetic stimulation pulses
- Other · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Injuries
- Interventions
- GFT AI training
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 14 Years to 22 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- Maribavir
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Overweight and Obesity
- Interventions
- Full LIITA3H App, Partial LIITA3H App, LIITA3H Location only
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- PreDiabetes
- Interventions
- Transform10 Diabetes Prevention Program
- Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- tideglusib, placebo
- Drug
- Lead sponsor
- Noscira SA
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 6
- States / cities
- Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 3 more
- Conditions
- Hepatic Impairment
- Interventions
- Radiprodil
- Drug
- Lead sponsor
- GRIN Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- DeSoto, Texas • San Antonio, Texas
- Conditions
- Healthy
- Interventions
- Glipizide and Metformin HCl Tablets 5 mg/500 mg, Metaglip® Tablets 5 mg/500 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Seborrheic Dermatitis
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- plant-based diet
- Behavioral
- Lead sponsor
- Physicians Committee for Responsible Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Healthy Volunteers
- Interventions
- Centanafadine SR, Centanafadine QD XR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Diabete Type 2, Obesity & Overweight, Nutritional Intervention, Food Insecurity
- Interventions
- Meal kits, No-prep meals, Culinary nutrition classes, Text messages
- Behavioral
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- PF-04447943
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Psoriasis
- Interventions
- Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
- Drug
- Lead sponsor
- Sirtris, a GSK Company
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Participants
- Interventions
- Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Sclerosis
- Interventions
- Tolebrutinib, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Healthy Subjects
- Interventions
- lemborexant, Loestrin, famotidine, fluconazole
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
- Interventions
- FMD, Regular Diet Plus FMD
- Dietary Supplement · Combination Product
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Long Beach, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
- Conditions
- Healthy
- Interventions
- Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Alcohol Use Disorder
- Interventions
- Virtual Practice Facilitation with e-Learning, Virtual Practice Facilitation without e-Learning
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado